Analysts Anticipate MediWound Ltd. (MDWD) Will Post Quarterly Sales of $740,000.00
Equities analysts expect that MediWound Ltd. (NASDAQ:MDWD) will post $740,000.00 in sales for the current quarter, Zacks reports. Three analysts have made estimates for MediWound’s earnings. The highest sales estimate is $820,000.00 and the lowest is $600,000.00. MediWound reported sales of $520,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 42.3%. The firm is expected to issue its next earnings report on Monday, November 13th.
According to Zacks, analysts expect that MediWound will report full year sales of $740,000.00 for the current year, with estimates ranging from $2.50 million to $3.40 million. For the next fiscal year, analysts expect that the company will post sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for MediWound.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. During the same period in the prior year, the company earned ($0.34) EPS. The firm’s revenue was up 93.8% compared to the same quarter last year.
Shares of MediWound (MDWD) traded down 2.49% during midday trading on Wednesday, reaching $4.90. 53,592 shares of the company’s stock were exchanged. The company’s 50 day moving average is $5.28 and its 200-day moving average is $6.30. MediWound has a 12 month low of $4.25 and a 12 month high of $8.25. The stock’s market cap is $107.57 million.
Several institutional investors have recently added to or reduced their stakes in MDWD. Wells Fargo & Company MN increased its stake in shares of MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares during the period. Wellington Management Group LLP increased its stake in shares of MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares during the period. Renaissance Technologies LLC increased its stake in shares of MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares during the period. Finally, Nationwide Fund Advisors acquired a new position in shares of MediWound in the third quarter valued at approximately $1,538,000. 19.54% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/25/analysts-anticipate-mediwound-ltd-mdwd-will-post-quarterly-sales-of-740000-00.html.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.